Untitled

doi:10.26479/2017.0304.09

Cited by 1 publication

(1 citation statement)

References 31 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5,6] Thus, 1,3-oxazole could be considered as perspective moiety in the design and further synthesis of novel biologically active agents that exert anticancer activity. [1][2][3][4][23][24][25][26][27][28][29][30][31][32][33][34] So, the QSAR models were developed for wide site of 1,3-oxazole derivatives showing inhibitory effect on the NCI-60 cancer cell lines, [2,35] and the well correlation was established between many descriptors and biological activity. So, it was investigated the interaction of the azole derivatives with the tubulin inhibitors which significantly improve the clinical effectivity of novel proposed biological active molecules as anticancer agents.…”

Section: Introductionmentioning

confidence: 99%

Dependence of the anticancer activity of 1,3‐oxazole derivatives on the donor/acceptor nature of his substitues

Kachaeva

Hodyna

Obernikhina

et al. 2019

Journal of Heterocyclic Chem

View full text Add to dashboard Cite

A series of new 1,3‐oxazole derivatives, containing in position 5 both donor and acceptor substituents were synthesized. These substances were considered as potentially active anticancer pharmacophores in the human tumor cell line panel derived from nine cancer types, including lung, colon, melanoma, renal, ovarian, brain, leukemia, breast, and prostate. Primary in vitro one‐dose anticancer screening was shown that compounds with acceptor substituents (such as –C(O)OMe, –CN) in the position 5 inhibit the growth of most cell lines, and compounds with donor substituents (such as –NHR, −SR) in the position 5 do not practically inhibit the growth of cancer cell lines. It can be assumed that the pharmacological activity of 1,3‐oxazole derivatives depends on donor/acceptor nature of the substituents in position 5. It was proposed to evaluate the donor/acceptor ability of 1,3‐oxazole derivatives using the special parameter φ0, which takes into account the relative position of the boundary levels (HOMO end LUMO). The quantum‐chemical modeling was performed; the special parameter φ0 for 1,3‐oxazole derivatives correlates with the experimental results. Quantum‐chemical calculations of the special parameter φ0 allow modeling the pharmacological activity of 1,3‐oxazole derivatives by introducing donor or acceptor substituents at position 2 or 5. This work may be useful for chemists to develop a target synthesis of potential biologically active compounds.

show abstract